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Antibodies against P. falciparum merozoites fix complement to inhibit blood-stage replication
in naturally-acquired and vaccine-induced immunity; however, specific targets of these
functional antibodies and their importance in protective immunity are unknown. Among
malaria-exposed individuals, we show that complement-fixing antibodies to merozoites are
more strongly correlated with protective immunity than antibodies that inhibit growth
quantified using the current reference assay for merozoite vaccine evaluation. We identify
merozoite targets of complement-fixing antibodies and identify antigen-specific complement-
fixing antibodies that are strongly associated with protection from malaria in a longitudinal
study of children. Using statistical modelling, combining three different antigens targeted by
complement-fixing antibodies could increase the potential protective effect to over 95%, and
we identify antigens that were common in the most protective combinations. Our findings
support antibody-complement interactions against merozoite antigens as important anti-
malaria immune mechanisms, and identify specific merozoite antigens for further evaluation
as vaccine candidates.
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Despite gains made through increased control efforts,malaria remains a significant health and economic burdenglobally, and progress in reducing the malaria burden is
stalling in recent years1. The RTS,S/AS01 subunit vaccine tar-
geting the P. falciparum pre-erythrocytic stage is now entering
phase 4 implementation trials; however, with low vaccine efficacy
of 18.3–36.3% depending on age and vaccine regimen, it is clear
that second generation malaria vaccines will be needed2. In
naturally acquired immunity to malaria, antibodies targeting
merozoites during blood-stage infection play important roles in
protective immunity, as demonstrated by several lines of evi-
dence3–8. As such, targeting merozoite antigens is a key strategy
of vaccines aimed at limiting parasite replication and parasite
burden, thereby preventing clinical disease5. However, a limited
understanding of key protective antigens and mechanisms of
antibody-mediated protection hampers the identification and
prioritization of specific merozoite antigens and combinations as
vaccine candidates. Establishing of correlates of protection is a
priority topic in the Malaria Vaccine Technology Roadmap9.
Current in vitro immunoassays have proven inconsistent or
insensitive as correlates of immunity in vaccine or population
studies, adding to the difficulties in advancing vaccine antigens8.
Antibodies quantified by ELISA do not consistently correlate with
protective immunity from malaria and often they do not reflect
the functional activity of antibodies10–17. The current standard
assay for quantifying functional activity of merozoite antigen
vaccines, the growth inhibition assay (GIA), quantifies the ability
of antibodies to inhibit parasite replication in vitro. While activity
in GIA has shown predictive value in some pre-clinical animal
models, antibody activity in GIAs has not reliably correlated with
protective immunity in studies of naturally acquired immunity or
in clinical vaccine trials10,13,16,18–23.
Recent studies demonstrated that acquired and vaccine-
induced human antibodies to merozoite antigens can fix and
activate serum complement, leading to inhibition of RBC inva-
sion and merozoite death24,25. It was found that a large propor-
tion of naturally acquired human antibodies only effectively
prevented merozoite invasion in the presence of complement24. A
role for complement is further supported by associations between
protection from malaria and levels of cytophilic IgG1 and IgG3,
which can activate the classical complement cascade by binding
C1q26–30. This important role of complement in human antibody
function may explain why standard in vitro GIAs, which
are performed in complement-free conditions, are neither
strongly nor consistently associated with protection10,13,21,31,32.
Given these assays are still used as a gold standard to assess
and prioritize vaccine candidates, important targets of functional
antibodies might be missed19,33,34. Roles for antibody-
complement interactions have also been recently reported for
immunity to sporozoites35–37, suggesting that antibody-
complement interactions have wider roles in immunity against
multiple stages of malaria.
Specific antigen targets mediating complement-dependent
protection are currently unknown. Initial studies demonstrated
that antibodies to MSP1 and MSP2 could mediate complement-
dependent invasion-inhibitory activity in vitro24, but the roles of
these target-specific complement-dependent antibodies in pro-
tective immunity are yet to be explored, and other potential
candidates have not been assessed. Although recent gains have
been made in defining mechanisms of immunity to malaria8,
there is a paucity of data on protective associations for a range of
antigen-specific functional responses in human studies; to date,
studies assessing responses to multiple merozoite antigens have
only assessed IgG reactivity using standard immunossays, such as
ELISA and protein microarrays31,38,39. Furthermore, there is a
lack of validated and practical in vitro assays to quantify
functional antibody responses to a range of individual antigens in
studies of naturally-acquired immunity in populations where
antibodies with a broad range of specificities are acquired.
The prior finding that complement-fixing antibodies to whole
intact merozoites were highly correlated with protection from
clinical malaria and high-density parasitemia in children24 pro-
vided a strong rationale to identify specific antigen targets of these
antibodies that are linked with protective immunity. Here, we
compare protective associations for complement-fixing antibodies
with the current reference functional assay, GIA. We develop
optimized assays that quantify complement-fixing antibodies to
individual merozoite surface proteins and define the acquisition
of complement-fixing antibodies to a range of merozoite antigens.
In a longitudinal cohort study of children, we apply our novel
strategy to identify specific antigens that are targets of
complement-fixing antibodies associated with protection. Using
statistical models, we evaluate protective associations for all
possible combinations of responses and identify antigen-specific
complement-fixing antibody combinations that give the strongest
protective associations. These findings will help enable potential
vaccine candidates to be selected and prioritised based on func-
tional activity.
Results
Complement-fixing antibodies more strongly associated with
protection than GIA. We previously determined that
complement-fixing antibodies to whole merozoites were asso-
ciated with protection against clinical malaria in a longitudinal
cohort of children in a malaria-endemic region of Papua New
Guinea (PNG)24. GIA is currently the standard assay used to
evaluate functional antibodies to merozoites and, therefore, we
evaluated GIA activity among the same children’s cohort and
compared their relationship with protection from malaria to that
for complement-fixing antibodies (which was assessed as fixation
of the first component of the classical complement cascade, C1q,
to the surface of merozoites24). The Cox proportional hazards
model was used to determine the hazard ratio (HR) for pro-
spective risk of malaria over 6 months follow-up among children
with different levels of complement-fixing and GIA functional
antibodies, with adjustment (adjusted HR, aHR) for established
confounders of age and location of residence24. In contrast to the
strong association between complement-fixing antibodies with
protection from clinical malaria (high vs low responders aHR=
0.15 (95% CI 0.06–0.35, p < 0.0001), inhibitory activity quantified
by standard GIA was only weakly associated with protective
immunity (high vs low responders aHR= 0.60 (95% CI,
0.33–1.09; p= 0.094) (Fig. 1a; Supplementary Fig. 1) confirming a
greater protective association of complement-fixing antibodies.
The protective association ((1-HR) x 100%) of complement-fixing
antibodies was 45% higher (absolute difference) than growth-
inhibitory antibodies.
To investigate relationships between antibody parameters
further, we tested a selection of cohort samples in antibody-
complement invasion inhibition assays (AbC-IIA) using purified
merozoites24. Invasion in the presence of antibodies and
complement, was negatively correlated with C1q-fixation to the
merozoite surface (r=−0.62, 95% CI −0.81–0.30, p= 0.0006
[Spearman’s rho], Fig. 1b), consistent with our prior conclusion
that complement is important for inhibitory activity of anti-
bodies24. In contrast, we observed no significant correlation
between antibody-mediated C1q-fixation and activity in standard
GIA, which is performed in complement-free conditions (r=
−0.29, 95% CI −0.61–0.12, p= 0.15 Fig. 1c). There was some
correlation between activity in AbC-IIA and GIA (both measured
as invasion/growth, r= 0.4, 95% CI 0.02–0.69, p= 0.035, Fig. 1d);
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as noted previously, some antibodies can act to inhibit invasion
independent of complement24. We also observed a significant
difference in AbC-IIA functional activity between groups when
cohort participants were stratified into tertiles according to low,
medium and high C1q fixation to the merozoite’s surface. There
was higher median invasion (less inhibition) in the group of low
C1q fixation compared to medium and high C1q fixation
(Fig. 1e). However, there were no significant differences in
activity in GIAs between the groups (Fig. 1f).
Development of an antigen-specific complement-fixation assay.
Given the strong protective association for antibody-
complement-fixation on the merozoite surface, we aimed to
identify specific merozoite antigens that were targets of poten-
tially protective, complement-fixing antibodies. We first devel-
oped a plate-based assay to detect and quantify complement-
fixing antibodies to individual merozoite antigens. Antigens were
coated onto plates, incubated with individual, heat-inactivated
(complement-inactive) serum samples from a cohort of children
as a source of antibodies, followed by incubation with purified
C1q (pC1q). C1q-fixation was detected as a measure of
complement-fixing activity of antibodies. To validate pC1q, a
selection of PNG adult’s and children’s serum samples from a
cross-sectional cohort40 was tested using pC1q versus normal
serum (NS, complement active) as the source of C1q, on the
major merozoite antigen MSP2 (FC27-allele). There was a strong
positive correlation between assays with pC1q versus normal
serum (r= 0.95, p < 0.0001 [Spearman’s rho]) (Supplementary
Fig. 2). The use of pC1q was favoured for subsequent assays
because it facilitated the use of standardized reagents.
We demonstrated that fixation of C1q by antibodies resulted in
the activation of the entire complement cascade by investigating
the correlation between C1q fixation and the formation of C5b-
C9 which forms the membrane attack complex (MAC), using
selected merozoite antigens as antibody targets and adult and
children serum samples from a cross-sectional study in PNG.
C1q-fixation on EBA175RII, MSP2 (FC27) and MSP-DBL1
correlated strongly with levels of MAC formation on the
respective antigen, using normal serum as a complement source
(r= 0.82–0.98, all p < 0.0001, Fig. 2a). To confirm that MAC
formation resulted from fixation of C1q, we tested antibody-
mediated complement fixation using either normal serum, heat-
inactivated serum or C1q-depleted serum as the source of
complement factors. C1q-fixation and MAC formation were
greatly reduced in heat-inactivated serum or C1q-depleted serum
compared to normal serum (Fig. 2b and Supplementary Fig. 3A).
Furthermore, we tested a human monoclonal antibody (mAb)
against MSP2 (FC27) that had two leucine-to-alanine conversions
(L234A and L235A, LALA mutant); this mutation in the Fc
region results in reduced C1q binding41. While both wild type
and mutant mAbs bound to MSP2 to the same extent
(Supplementary Fig. 3B), the ability of the mutant mAb to bind
and fix C1q, leading to activation of the complement cascade and
MAC formation, was greatly reduced compared to wild-type mAb
for C1q fixation and MAC formation (>10-fold and >30-fold,
respectively). The mAbs were tested at a concentration (5 μg/ml)
that reached maximum detection of MAC formation for wild type
(Fig. 2c, d).
Acquisition of complement-fixing antibodies in children. We
next examined the prevalence and magnitude of C1q-binding
antibodies against a range of merozoite antigens in a longitudinal
cohort of PNG children42. Antigens included were selected on the
basis of pre-screening using samples from a cross-sectional study
including malaria-exposed samples from adults in the same
population43 (representative examples are shown in Supplemen-
tary Fig. 4). Results from this screen showed that C1q-fixation
was variable amongst different merozoite antigens, and not all
high IgG responders to a given antigen had also high levels of C1q
fixation. Antigens with no or very low detectable C1q-fixation in
the pre-screen were not included in the longitudinal cohort;
excluded antigens were PfRH4.9, Pf12, Pf38, Pf41 and SERA5. A
total of n= 22 antigens were tested for complement-fixing anti-
bodies in the longitudinal cohort. The tested antigens comprised
established and emerging vaccine candidates: MSP1–19,
MSP1–42, MSP2 (3D7 and FC27 alleles), MSP3, MSP4, MSP6,
MSP7, MSP9, MSP10, MSPDBL1, AMA1, EBA140 region II
(RII), EBA140 region III-V (RIII-V), EBA175 RII, EBA175 RIII-
V, PfRH2-2030, PfRH5, Ripr, GAMA, RALP1 and Pf113.
C1q-fixing antibodies in the longitudinal cohort were detected
in the majority of children for each recombinant antigen tested.
The prevalence of C1q-fixing antibodies to most antigens was
greater than 90% (13 out of 22; MSP1–19, MSP1–42, MSP2
(3D7), MSP4, MSP6, MSP7, MSP9, AMA1, EBA140RII,
EBA140RIII-V, EBA175 RII, RH2-2030 and GAMA, Supplemen-
tary Table 1). The targets with the lowest prevalence of C1q-fixing
antibodies were MSP3 (31.8%), PfRH5 (57.4%), Pf113 (60.3%)
and MSP10 (64.1%).
For the majority of antigens tested, the level and prevalence of
C1q-fixing antibodies was higher among older children, con-
sistent with the acquisition of functional antibodies with age and
cumulative exposure (Table 1 and Supplementary Table 1).
Complement-fixing antibodies were also higher in magnitude and
prevalence in children with P. falciparum parasitemia at the time
of sample collection, consistent with boosting of functional
antibodies by active infection.
C1q-fixing activity to most merozoite proteins were strongly
correlated with C1q-fixing activity to the intact merozoite surface
(Fig. 3; representative examples shown in Supplementary Fig. 5;
range from r= 0.29, 95% CI 0.15–0.41 (Ripr) to r= 0.80, 95% CI
0.74–0.84 (EBA140RIII-V), 9/22 comparisons r > 0.6 and 7/22
comparisons r > 0.7; all comparisons p < 0.0001 [Spearman’s
rho]). Complement-fixing antibodies to individual surface
proteins were generally moderately (r > 0.5) to highly (r > 0.6)
positively correlated, suggesting co-acquisition of complement-
fixing antibodies to multiple targets from malaria infections
(Fig. 3). However, low-level correlations were generally observed
for responses to MSP3, Ripr and Pf113 and all other antigens,
respectively. Complement-fixing antibodies to the two different
alleles of MSP2 (3D7 and FC27) were only moderately correlated
(r= 0.506, p < 0.001), consistent with findings that naturally
acquired antibodies largely target allele-specific epitopes44. The
correlation coefficients between total IgG reactivity and C1q-
fixation to an antigen were variable among antigens with the
weakest correlations observed for MSP3 (r= 0.29, 95% CI
0.16–0.42), Ripr (r= 0.46, 95% CI 0.34–0.57), PfRH5 (r= 0.48,
95% CI 0.36–0.59) and MSP1–19 (r= 0.57, 95% CI 0.47–0.66);
The strongest correlations were observed for AMA1 (r= 0.95,
95% CI 0.93–0.96), MSP4 (r= 0.92, 95% CI 0.90–0.94) and
EBA175RII (r= 0.92, 95% CI 0.90–0.94) (Supplementary
Table 2).
Function correlates with cytophilic subclasses but weakly with
avidity. The correlations between C1q-fixing antibodies and IgG
subclasses to selected merozoite antigens, namely MSP2, GAMA,
AMA1 and MSP-DBL1 as representative results, were explored.
IgG1 and IgG3 subclasses can effectively fix complement, whereas
IgG2 and IgG4 have little or no activity45; therefore, correlations
for IgG1 and IgG3 were evaluated. It was previously demon-
strated that IgG1 and IgG3 are the dominant responses to
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merozoite antigens in this population, with very little IgG2 and
IgG427,29,46,47. MSP2-specific IgG3 levels were strongly correlated
with C1q-fixing antibodies to MSP2 (r= 0.84, 95% CI 0.79–0.88,
p < 0.0001 [Spearman’s rho]), and this correlation was weaker
between IgG1 and C1q-fixing antibodies (r= 0.39, 95% CI
0.26–0.50, p < 0.0001; Fig. 4a). For AMA1, both IgG1 and IgG3
were significantly correlated with the presence of C1q-fixing
antibodies, however, the IgG1 response was much stronger
(Fig. 4c, r= 0.89, 95% CI 0.85–0.91, p < 0.0001, and r= 0.60, 95%
CI 0.51–0.69, p < 00001, respectively). For GAMA and MSP-
DBL1 we observed moderate to strong positive correlations
between the presence of IgG1 and IgG3, and antibody-dependent
C1q fixation (Fig. 4b, d). IgM responses to merozoite antigens
may also contribute to complement fixation, and we examined
correlations to several antigens to explore this. IgM reactivity was
also significantly correlated with complement fixation (r= 0.38
for MSP2; r= 0.69 for EBA140II; r= 0.53 for EBA175III-V; p <
0.0001 for all [n= 194–197]).
Using samples from the cross-sectional cohort of adults and
children, we analysed the association between C1q fixation on
MSP2 and the avidity of MSP2 antibodies as measured by surface
plasmon resonance (SPR). There was a weak correlation between
C1q fixation and increased avidity of antibodies measured as kd
against MSP2 (3D7 allele) (r=−0.24, p= 0.05), and no
association between C1q fixation and avidity of antibodies against
MSP2 (Fc27) (r=−0.07, p= 0.56; Supplementary Fig. 6). To
explore the relative contributions of IgG magnitude and antibody
avidity to complement-fixing activity, we performed linear
regression analysis. The addition of avidity as a predictor variable
did not substantially increase R2 for the relationship between IgG
and complement-fixation (0.8652 compared to 0.8613 with total
IgG as a predictor alone), further suggesting that antibody avidity
levels are not a major determinant of complement fixation.
Antigen-specific complement-fixing antibodies and protection
from malaria. To identify targets of complement-fixing anti-
bodies that may be important for protection from malaria, we
analysed associations between complement (C1q) fixation to all
antigens individually and protection from clinical malaria and
high-density parasitemia over 6 months of follow up in the
longitudinal cohort of PNG children. Children were classified
into three equal groups (low, medium and high) based on
complement-fixing antibodies activity for each antigen. We
analysed the relationship between antibody categories and time to
clinical episode, or high-density parasitemia infection (Supple-
mentary Tables 3–5 for additional comparisons). Hazard ratios
(Cox proportional hazards) were adjusted for known con-
founders, age and location42. We observed statistically significant
associations for most antigens, and the strength of protective
associations varied substantially between antigens, with a range
from aHR 0.20 [0.10–0.43] to 1.07 [0.72–2.35] (Fig. 5a; Supple-
mentary Fig. 7; Supplementary Tables 3–5). The 10 antigens with
the strongest association with protection were EBA140RIII-V
(aHR= 0.20), MSP7 (aHR= 0.23), RALP1 (aHR= 0.24), GAMA
(aHR= 0.27), PfRH2 (aHR= 0.30), MSP-DBL1 (aHR= 0.33),
PfRH5 (aHR= 0.37), EBA175-RIII-V (aHR= 0.41) and MSP2-
3D7 (aHR= 0.41) (Fig. 5a). Complement-fixing antibodies to
MSP1–19 had a significant association with protection, which
supports our previous finding that antibodies against MSP1–19
mediate complement-dependent invasion inhibition24.
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Fig. 1 Protective associations and correlation between antibody-dependent fixation of C1q and complement-dependent invasion inhibition or GIA. a A
longitudinal cohort of PNG children was used to calculate protective associations for functional antibodies as determined in Growth Inhibition Assays (GIA,
complement-free conditions, n= 205, Mugil cohort) and C1q-fixation assays on the merozoite surface (n= 200). Children were stratified into three equal
tertiles (based on ranks) and adjusted hazard ratios (aHR) were calculated using Cox proportional hazards model comparing high versus low (HvL) and
medium versus low (MvL) responders. Black bars compare high versus low responders (HvL), grey bars compare medium versus low responders (MvL).
b The correlation between C1q fixation on the merozoite surface and activity in antibody-complement invasion inhibition assays (IIA) among a subset of
samples (n= 27) (data are shown as invasion (%) relative to controls). c The correlation between C1q fixation and activity in growth inhibition assays
(GIAs) among the same subset of samples (n= 27) (data are shown as growth (%) relative to controls). d Shows the correlation between antibody-
complement IIA and GIA among a subset of samples (n= 27). Spearman’s rho (r) and statistical significance (p) are indicated. Non-linear regression was
used to generate a trendline. Dotted lines indicate 95% confidence intervals. e, f Study participants (n= 27) were stratified into three equal tertiles
according to low, medium and high C1q fixation to the merozoite surface. The median invasion measured by antibody-complement IIA (e) and growth
measured by GIA (f) was compared between the three groups (statistical significance determined by Kruskal–Wallis test)
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associated with protection; antibodies to MSP1–42, MSP4, and
MSP2-FC27 showed a trend towards protective associations with
aHR ranging from 0.54–0.62. Naturally acquired antibodies to
MSP2 are known to be largely allele-specific (3D7 and FC27
alleles)24,25 and infections with both alleles occurred in our study
population (although 3D7 is ~2-times more common than
FC2727,29). Therefore, we analysed associations with protection
considering both allelic responses. Children were classified as
2.5







































































































































































































Fig. 2 Antibody-dependent fixation of C1q and detection of downstream factors of the complement cascade. a Figures show the correlation between
antibody-mediated fixation of C1q or membrane attack complex (MAC) among a selection of samples from the XMX cohort. Results are shown for three
recombinant proteins: EBA175RII (n= 48), MSP2 (FC27) (n= 43) and MSPDBL1 (n= 44). Spearman rho and p values are shown. Non-linear regression
was used to generate a trendline, and dotted lines indicate 95% confidence intervals. Values on the x-axes and y-axes represent OD values (405 nm) for
MAC reactivity or C1q activity, respectively. b Complement-fixing activity of antibodies was determined using a selection of samples (n= 14, XMX cohort)
against MSP2 recombinant protein as the target. MAC formation was determined using normal serum (NS) or C1q-depleted serum in plate-based assays.
Results are shown as mean ODs from 2 independent assays, performed in duplicate. Error bars represent range; x-axis: serum samples A-N. c, d
Complement-fixation activity of a human monoclonal antibody against MSP2; the wild-type form was compared to its mutant version (LALA) that had 2
Leucine-to-Alanine conversions (L234A, L235A), which is known to inhibit C1q binding. Antibodies were tested for their ability to fix C1q (c) and promote
MAC formation (d). Concentrations of antibody are indicated on the x-axis as [µg/ml]. Results are shown as the mean of two assays performed in
duplicate. Error bars represent range
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high, medium, or low responders to each allele (tertiles based on
ranks using C1q-fixation data), and subsequently grouped
according to response levels to both alleles. Children who were
high responders to both alleles had a strong protective association
(aHR= 0.219 [0.06–0.73]) compared to children who were in the
lower response group (which included low responders to both
alleles and those who were low responders to one allele and a
medium responder to the other allele). Of interest, the number of
antigens with strong and intermediate associations with protec-
tion was >2-fold higher for apical proteins compared to surface
proteins, suggesting that antigens residing in the apical organelles
are key targets of protective complement-fixing antibodies
(Fig. 5b).
In order to account for potential problems in analysis of
protective associations that may arise if some children are not
exposed during the period of follow-up48, we performed a
sensitivity analysis for complement fixation on whole merozoites
including only those children who became re-infected (detected
by PCR) over the course of the follow-up period (n= 191
compared to n= 200). This had no impact on the results (aHR all
children: 0.15 [0.06–0.35, p < 0.0001; aHR re-infected children
only: 0.14 [0.06–0.33], p < 0.0001).
Breadth of complement-fixing antibodies predicts protection.
To investigate the breadth of complement-fixing antibodies and
protective immunity, we assigned each participant in our cohort a
breadth score based on the level of reactivity to each of the 22
antigens included in the study. Cox regression analysis showed a
strong protective association against clinical malaria among
children with a high breadth score compared with a low breadth
score (aHR 0.27, 95% CI 0.13–0.54, p < 0.0001 [Cox proportional
hazards]). There was significantly increased breadth score in older
children compared to younger children, and in children who were
parasitemic at enrolment compared to aparasitemic children (p ≤
0.01; Fig. 5c, d, see Supplementary Fig. 8 for breadth score dis-
tributions), consistent with acquisition of a repertoire of func-
tional antibodies with increasing age and exposure. Furthermore,
the breadth score was significantly higher in children that were
protected and did not experience any clinical episodes during
follow up compared to children who experienced one malaria
episode (susceptible 1) or 2 or more malaria episodes (susceptible
2, p= 0.0001, Fig. 5e [Kruskal–Wallis test]).
Combinations of antibody responses and protection from
malaria. We investigated the protective associations of combined
responses to multiple antigens on to understand how protection
against malaria relates to functional antibodies to multiple anti-
gens, and to identify antigen combinations with the highest
protective associations that may inform vaccine development. We
evaluated potential protective efficacy (PPE), which was calcu-
lated as (1-Hazard Ratio)*100), where 100% represents complete
protection. We included responses against 20 different antigens
(all antigens except MSP1–42 since it is part of the same antigen
as MSP1–19, and only the 3D7 and not FC27 allele of MSP2).
Antigens were grouped into all possible combinations of
responses of 2, 3, 4, 5, or 6 antigens (190, 1140, 4845, 15504, and
38760 combinations, respectively; n= 20 antigens were included).
We found that the PPE and the frequency of highly protective
combinations (PPE >75%) increased with increasing breadth of
responses (Fig. 6a). PPE increased substantially up to combina-
tions of 3 antigens; increasing the combination size to 4–6
antigens gave only minor improvements in PPE. Interestingly, the
PPE for the best combination of three antigens was very high
(93.6% [95% CI 81.9–97.7]) and similar to the best combinations
of 4, 5 or 6 antigens (Fig. 6b). We then ranked the PPE of all
possible combinations of a given size, and calculated the median
PPE of the top 100 combinations for each combination size
(Fig. 6c). The median PPE of the top 100 combinations in each
Table 1 Magnitude of complement-fixing antibodies against merozoite antigens
Antigen Age Enrolment P. falciparum parasitemic status
<9 yrs na ≥9 yrs na Pc PCR- na PCR+ na Pb
Merozoites 0.24 [0.14–0.33] 0.35 [0.26–0.43] <0.0001 0.23 [0.08–0.34] 0.34 [0.23–0.43] <0.0001
MSP1–19 0.26 [0.19–0.42] 0.29 [0.19–0.51] 0.3 0.23 [0.17–0.37] 0.29 [0.2–0.49] 0.05
MSP1–42 0.15 [0.04–0.42] 0.29 [0.11–0.6] 0.007 0.11 [0.02–0.33] 0.32 [0.12–0.57] <0.0001
MSP2 (3D7) 0.1 [0.04–0.21] 0.164 [0.09–0.28] 0.003 0.07 [0.03–0.17] 0.17 [0.09–0.28] <0.0001
MSP2 (FC27) 0.04 [0.009–0.15] 0.09 [0.02–0.47] 0.03 0.02 [0.001–0.1] 0.1 [0.02–0.42] <0.0001
MSP3 0.24 [0.17–0.35] 0.22 [0.15–0.34] 0.2 0.19 [0.12–0.25] 0.25 [0.18–0.37] 0.0004
MSP4 0.14 [0.05–0.35] 0.22 [0.12–0.48] 0.007 0.1 [0.04–0.19] 0.25 [0.12–0.57] <0.0001
MSP6 0.17 [0.11–0.42] 0.24 [0.13–0.52] 0.19 0.14 [0.08–0.27] 0.25 [0.14–0.52] 0.0003
MSP7 0.34 [0.17–0.58] 0.42 [0.22–0.68] 0.08 0.23 [0.11–0.46] 0.44 [0.28–0.75] <0.0001
MSP9 0.08 [0.06–0.14] 0.17 [0.08–0.35] <0.0001 0.07 [0.05–0.13] 0.16 [0.09–0.33] <0.0001
MSP10 0.25 [0.13–0.42] 0.29 [0.16–0.54] 0.2 0.18 [0.11–0.32] 0.31 [0.18–0.54] 0.0001
MSP-DBL1 0.44 [0.1–1.06] 0.62 [0.21–1.37] 0.05 0.22 [0.07–0.94] 0.65 [0.26–1.27] 0.003
Ripr 0.34 [0.23–0.46] 0.31 [0.2–0.56] 0.86 0.26 [0.18–0.48] 0.33 [0.24–0.53] 0.03
GAMA 0.27 [0.16–0.57] 0.43 [0.29–0.59] 0.006 0.25 [0.13–0.45] 0.44 [0.27–0.61] <0.0001
RALP1 0.15 [0.08–0.36] 0.38 [0.18–0.66] <0.0001 0.16 [0.09–0.33] 0.33 [0.15–0.6] 0.0002
AMA1 0.26 [0.08–0.82] 0.38 [0.18–0.78] 0.056 0.16 [0.04–0.47] 0.48 [0.22–0.96] <0.0001
EBA140 RII 0.89 [0.44–1.25] 1.05 [0.65–1.36] 0.02 0.85 [0.29–1.3] 1.03 [0.69–1.32] 0.08
EBA140 RIII-V 0.1 [0.05–0.26] 0.18 [0.08–0.39] 0.01 0.09 [0.05–0.2] 0.19 [0.09–0.46] <0.0001
EBA175RIII-V 0.14 [0.07–0.30] 0.26 [0.14–0.64] 0.0006 0.12 [0.07–0.26] 0.25 [0.13–0.66] <0.0001
EBA175RII 0.70 [0.08–1.33] 1.04 [0.28–1.43] 0.013 0.28 [0.04–0.85] 1.12 [0.33–1.43] <0.0001
Rh2–2030 0.26 [0.1–0.49] 0.3 [0.14–0.50] 0.22 0.16 [0.08–0.38] 0.31 [0.17–0.56] 0.0001
PfRh5 0.19 [0.15–0.29] 0.26 [0.17–0.41] 0.01 0.17 [0.12–0.26] 0.25 [0.17–0.38] 0.0004
Pf113 0.07 [0.04–0.12] 0.1 [0.06–0.17] 0.03 0.06 [0.03–0.12] 0.09 [0.05–0.16] 0.008
Median optical density [OD] and interquartile range [IQR] are displayed. The 3D7 reference strain was used for all antigens; the FC27 strain was also assessed for MSP2
aNumbers (n) analysed (n < 9 yrs, n≥ 9 yrs, n PCR-, n PCR+) are as follows: 87, 109, 64, 132 for MSPDBL1, MSP7, GAMA, RALP1; 87, 110, 64, 133 for MSP6, EBA140RII, EBA140RIII-V, Rh5; 88, 110, 64,
133 for MSP1–42, EBA175RIII-V; 90, 110, 65, 135 for Merozoites, MSP1–19, EBA175RII, MSP2 (3D7 and FC27); 90, 111, 65, 136 for MSP4, AMA1; 90, 114, 65, 139 for Ripr; RH2–2030: 88, 110, 64, 134;
MSP9: 84, 109, 63, 130; MSP10: 88, 104, 62, 130; Pf113: 85, 94, 58, 121
b,cp indicates statistical significance (Wilcoxon rank-sum tests)
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group rose with increasing combination size; however, this was
most striking up to combinations of three antigens and the gains
in PPE were modest when combination size was increased to four
or more (median PPE was 88.9, 92.9, 94.6 and 95.5% for
combinations of 3, 4, 5 and 6 antigens, respectively). Several
combinations had PPE >95% when three or more responses were
combined. Together, these findings suggest that an optimal
combination of three antigens might be sufficient for high
protective efficacy, or to act as a correlate of protection, and larger
combinations of antigens may offer limited benefit.
To determine which specific antigens in combinations may be
contributing most to PPE, we ranked all combinations based on
their PPE value and identified the top 1% of combinations with
the highest PPE; this was performed for each combination size (2,
3, 4, 5 and 6 antigens). We then then determined the frequency at
which a specific antigen was present in the top 1% PPE
combinations for each combination size (Table 2). For example,
among the highest-ranked 3-antigen combinations, RALP1,
MSP7 and Ripr, featured most commonly in the most protective
combinations (present in 100%, 72.7% and 36.4% of the top 1% of
combinations, respectively). EBA140-RIII-V, PfRH2 and MSP-
DBL1 responses were also common in the most protective
combinations (all 18.2%). Considering all combination sizes,
these antigens were generally frequent in the most protective
combinations. Interestingly, in the combinations of 5 and 6
antigens, PfRH5 (31.6% and 44.4%, respectively) and EBA175-RII
(32.3% and 35.1%, respectively) became more frequently present.
Discussion
Merozoite surface antigens have been the focus of much research
as important targets of human immunity and potential vaccine
candidates. However, identifying, validating and prioritizing
candidates has been challenging due to incomplete understanding
of mechanisms of immunity and targets of protective responses49,
and lack of methodologies that enable antigen-specific functional
antibodies to be systematically evaluated. We demonstrated that
complement-fixing antibodies to the intact merozoite surface are
more strongly associated with protective immunity than antibody
activity in standard GIA, which is the current reference assay for
evaluating merozoite vaccine antigens. Subsequently, we devel-
oped and validated an approach to quantify complement-fixing
antibodies to individual merozoite antigens for identifying
potential targets of protective complement-fixing antibodies.
Using this approach we identified several antigens with
complement-fixing antibodies that were very strongly associated
with protection from malaria, supporting their potential role as
immune targets and vaccine candidates and providing data sup-
porting ongoing development of several emerging vaccine can-
didates. Combining complement-fixing antibody responses
against as few as three specific antigens the PPE could be
increased to >95%, which supports the concept of a multi-antigen
vaccine approach.
Identifying and developing assays to assess immunologic cor-
relates of protection is priority area in the WHO Malaria Vaccine
Technology Roadmap9. Recent findings that human antibodies
interact with serum complement to inhibit merozoite invasion
and blood-stage replication provided the rationale for this study
to assess the importance of complement-fixing antibodies as
immune correlates relative to current widely used assays, and to
identify targets of complement-fixing human antibodies asso-
ciated with protective immunity. The low protective association
for antibodies quantified in GIA, which is performed in
complement-free conditions, is consistent with our previous
finding that the majority of acquired antibodies require comple-
ment interactions to effectively inhibit merozoite invasion24.
These findings have significant implications for evaluation of
vaccine candidates using GIA. While this assay maybe suitable for
a small number of antigen candidates where antibodies function
by direct blocking activity, our results strongly suggest that
complement-fixing antibodies are important for a wide range of
merozoite targets. Therefore complement-fixing assays should be
considered alongside other assays in vaccine development studies
and trials.
To identify specific antigens that were targeted by complement-
fixing antibodies we established an efficient plate-based assay to
quantify complement-fixing antibodies. We based this on fixation
of C1q, the first step in the classical (antibody-mediated)
MSP1–19 0.52
MSP1–42 0.72 0.49
MSP2–FC27 0.66 0.32 0.55
MSP2–3D7 0.68 0.39 0.59 0.51
MSP3 0.42 0.42 0.36 0.49 0.42 0.9
MSP4 0.72 0.32 0.63 0.66 0.66 0.40 0.8
MSP6 0.59 0.38 0.47 0.49 0.53 0.38 0.52 0.7
MSP7 0.69 0.30 0.60 0.58 0.61 0.42 0.60 0.59 0.6
MSP9 0.68 0.38 0.52 0.50 0.54 0.38 0.50 0.53 0.55 0.5
MSP10 0.71 0.52 0.61 0.61 0.58 0.70 0.63 0.54 0.64 0.57 0.4
MSP-DBL1 0.56 0.21 0.54 0.55 0.56 0.32 0.54 0.40 0.54 0.42 0.51 0.3
AMA1 0.63 0.35 0.61 0.52 0.60 0.35 0.69 0.38 0.53 0.34 0.60 0.50 0.2
EBA140RII 0.70 0.43 0.55 0.50 0.59 0.37 0.64 0.33 0.47 0.38 0.59 0.48 0.66 0.1
EBA140
RIII-V 0.80 0.60 0.66 0.62 0.65 0.51 0.65 0.62 0.70 0.58 0.72 0.53 0.66 0.67 0
EBA175RII 0.74 0.41 0.63 0.59 0.66 0.41 0.74 0.48 0.53 0.46 0.59 0.51 0.76 0.78 0.70
EBA175
RIII-V 0.75 0.54 0.66 0.65 0.67 0.51 0.71 0.57 0.58 0.59 0.68 0.45 0.62 0.64 0.73 0.74
PfRH2-
2030 0.72 0.44 0.68 0.55 0.59 0.41 0.62 0.47 0.66 0.49 0.66 0.52 0.65 0.63 0.72 0.68 0.61
PfRH5 0.44 0.36 0.40 0.38 0.39 0.30 0.35 0.50 0.47 0.42 0.41 0.23 0.28 0.20 0.45 0.37 0.45 0.47
Ripr 0.22 0.20 0.14 0.18 0.14 0.22 0.14 0.24 0.29 0.08 0.27 0.24 0.15 0.09 0.21 0.10 0.19 0.23 0.40
GAMA 0.70 0.48 0.51 0.49 0.50 0.19 0.51 0.40 0.52 0.50 0.51 0.36 0.45 0.49 0.67 0.48 0.58 0.52 0.35 0.18
RALP1 0.67 0.37 0.45 0.49 0.46 0.19 0.42 0.40 0.42 0.56 0.42 0.34 0.40 0.43 0.52 0.44 0.55 0.42 0.33 0.08 0.55
Pf113 0.32 0.43 0.34 0.40 0.44 0.43 0.37 0.39 0.32 0.53 0.50 0.21 0.19 0.17 0.34 0.25 0.43 0.23 0.46 0.18 0.33 0.26














PfRH5 Ripr GAMA RALP1
Fig. 3 Correlations between complement-fixing antibodies to different antigens. Spearman’s rho values indicate the level of correlation between C1q-fixing
antibodies against different merozoite antigens in children’s serum samples (n= 196–201). Correlates are coloured from red (highest level of correlation)
to green (lowest level of correlation). All correlations were significant except for comparisons between Ripr and MSP1–42, MSP2(3D7), MSP4, MSP9,
AMA1, EBA140RII, EBA175RII and RALP1, respectively (p > 0.05)
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complement activation pathway. We confirmed that C1q-fixation
led to complement activation and down-stream formation of the
MAC, and confirmed specificity by showing lack of activation when
using C1q-depleted serum or a recombinant human mAb with
LALA mutation in the Fc region, which ablates C1q binding.
Furthermore, complement fixation on merozoites correlated with
complement-dependent inhibition of invasion by antibodies.
Applying these approaches in a longitudinal cohort of children
acquiring immunity, we found substantial variation in the
complement-fixing activity between antigens, with some antibody-
antigen combinations showing limited complement-fixing ability
even in the presence of high levels of total IgG. These differences
may be partly explained by antibody epitope density on antigens
and orientation of bound antibodies, and differences in the balance
of IgG subclass responses27,29. Complement-fixing antibodies cor-
related with IgG1 and IgG3 responses, subclasses with known
complement-fixation potential. These findings are consistent with
the current understanding of malaria immunity where these cyto-
philic antibodies are associated with protective immunity28,29. IgM
reactivity to antigens also correlated with C1q-fixation, consistent
with the capacity of IgM to fix and activate complement. We found
little correlation between antibody avidity (measured by SPR) and
complement fixation, probably because human antibodies were
already above a threshold level of antibody avidity required for
complement fixation.
A striking finding was the very high protective association for
complement-fixing antibodies to some antigens. There was wide
variability in associations between complement-fixing antibodies
and protection for different antigens tested, with some antigens
having no or borderline protective associations. Interestingly, and
relevant to vaccine development efforts, the strongest protective
associations mostly included antigens that have not been a major
focus of vaccine development to date, or are emerging vaccine
candidates, including EBA140RIII-V, MSP7, RALP1, GAMA,
PfRH2, PfRH5 and MSP-DBL1. While identification of potential
vaccine targets has been accelerated by the increasing availability
of large genomic and proteomic data sets, the lack of functional
correlates of protection has been a significant hindrance for the
prioritization of vaccine candidates and the development of
much-needed correlates of protection5,50. The plate-based com-
plement-fixation assay optimised in this study is an important
step towards addressing this gap.
Our data further highlighted specific combinations of
responses that were very strongly associated with protective
immunity and indicated that the breadth of antigen-specific
functional antibodies is important in protective immunity.
Using statistical models to estimate the PPE for all combina-
tions of up to 6 antigens, combinations of 3 selected antigens
provide near-maximal PPE, and increasing combinations to 4
or more antigens offered marginal benefit. While these findings
are an encouraging step towards establishing correlates of
immunity, it is important to investigate these responses in
additional cohorts in future studies to understand the gen-
eralizability of our findings and to identify specific antigen
combinations that could be used across different populations as
a correlate of immunity. Evaluating different alleles of poly-
morphic antigens may also be informative. These findings also
have implications for antigen inclusion in vaccine design,
suggesting that specific combinations of 3–4 antigens might
provide good protective immunity. Antigens that were promi-
nent in protective combinations included RALP1, MSP7, Ripr,
EBA140-RIII-V, PfRH2, MSP-DBL1 and PfRH5. These findings
support further investigation of these antigens as potential
vaccine candidates. Interestingly, complement-fixing antibodies
to RALP1 and Ripr generally correlated only weakly or mod-
erately with responses to other antigens suggesting that they are
not strongly co-acquired with other responses. The strongest
correlation with Ripr responses was with PfRH5, with which it
forms a complex during invasion. PfRH5 is currently a leading
vaccine candidate and our findings that complement-fixing
antibodies to PfRH5 were strongly associated with protective
immunity and PfRH5 was frequently present in the most pro-
tective antibody combinations (Table 2) suggest that
complement-fixation should be evaluated in the ongoing clin-
ical trials of PfRH5 vaccines, alongside other assays assessing











































































































2.82.42.01.61.21.2 1.6 0.80.8 0.40.4 0.00.01.2 1.60.80.40.0
GAMA IgG3
r = 0.61, p < 0.0001
GAMA IgG1
MSPDBL1 IgG1AMA1 IgG3AMA1 IgG1
0.10.0 0.2 0.3
MSP2 IgG1 MSP2 IgG3
0.4 0.5
0.80.0 0.5 1.51.0 2.0 0.0 0.5 1.51.0 2.0
r = 0.54, p < 0.0001r = 0.60, p < 0.0001r = 0.89, p < 0.0001
r = 0.39, p < 0.0001 r = 0.84, p < 0.0001 r = 0.78, p < 0.0001 r = 0.68, p < 0.0001a b
c d
Fig. 4 Correlations between C1q-fixation and the presence of IgG1 and IgG3 subclass antibodies against selected merozoite antigens. The correlation
between the presence of antigen-specific, C1q-fixing antibodies and the presence of IgG1 or IgG3 is shown. a MSP2; b GAMA; c AMA1 (3D7); d MSPDBL1.
Results are shown as OD values. Spearman’s rho (r) and statistical significance (p) are indicated. Non-linear regression has been used to generate a fitted
line, dotted lines are showing 95% confidence interval bands (n= 196–201)
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Prior studies have established that antibody-complement
interactions can act to directly inhibit merozoite invasion and
lyse merozoites through the activation of complement on the
merozoite surface. Other potential mechanisms of complement
may also be important for parasite clearance and immunity
in vivo, such as the ability of complement to promote phagocy-
tosis by immune cells and promote immune activation; these
should be investigated in future studies. While murine models
can be valuable for investigating immune mechanisms in vivo and
evaluating candidate vaccines, current models have major lim-
itations for investigating antibody-complement interactions.
Murine responses to malaria infection or vaccination are pre-
dominated by IgG subclasses that do not fix complement, in
contrast to the complement-fixing IgG1 and IgG3 subclasses that
are predominant in human immunity8. Further, complement
activity in laboratory mice used is ~40-times lower than
humans51. Additionally, many of the major targets of
complement-fixing antibodies that we identified are either not
present in the rodent malaria species used in murine models, or
orthologues differ substantially from P. falciparum8. Investment
in establishing mouse or rat models of antibody-complement
immunity is warranted to advance our understanding of these
mechanisms in immunity and vaccine development.
In conclusion, our novel approach has addressed key gaps in
knowledge of human immunity by identifying targets of
complement-fixing antibodies and specific combinations of
responses that are strongly linked with protective immunity to
malaria. Our findings highlight several less-studied merozoite
antigens as important immune targets that should be further
evaluated as vaccine candidates, and supportive data for some
emerging candidates. Moreover, we identified combinations of
specific responses that may serve as valuable biomarkers of
immunity in malaria-exposed and vaccinated individuals. The
scalability of our plate-based complement-fixation assays could be
applied to track differences between populations or within-
populations over time, facilitating identifying populations at risk
of malaria epidemics due to waning immunity52. Our optimised
and reproducible assay provides a valuable tool with which to
study the acquisition of immunity and assess vaccine efficacy. The
identification of complement-fixing antibodies to specific anti-
gens and antigen combinations provides new leads for investi-
gation as potential vaccine targets.
Methods
Human subjects and samples. Ethical approval for the use of human serum and
plasma samples in these studies was obtained from the Alfred Human Research and
Ethics Committee for the Burnet Institute (protocol 435.10, 327.12), the Medical
Research Advisory Committee of Papua New Guinea (protocols 98.03, 05.20.01.13)
and the Human Research and Ethics Committee of the Walter and Eliza Hall Institute
(protocol 04.04, 06.01, 06.06). Written informed consent was obtained from all
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Fig. 5 Complement-fixing antibodies against merozoite antigens are associated with protection from malaria. a Adjusted Hazard Ratios (aHR) for each
antigen are plotted, ranked from highest to lowest based on analysis of samples and data from the Mugil cohort; the aHR for whole merozoites in also
shown. aHRs were calculated using the Cox proportional hazards model, comparing high responders versus low responders, and were adjusted for
confounders. Error bars indicate 95% confidence intervals. The red line indicates 0% protection (HR= 1.0). b Antigens were classified into tertiles
according to weak (n= 7), intermediate (n= 7) and strong associations with protection (n= 6) from clinical malaria episodes; pie charts show the
proportion of surface proteins or apical proteins associated with weak, intermediate or strong protection levels. Total n= 20 antigens; MSP1–42 was
excluded since it is part of the same antigen as MSP1–19, and only one allele of MSP2 (3D7) was included. c The median breadth score of antibodies is
shown stratified by age (< or >9 years of age, n= 91 or n= 115) or d PCR status at enrolment, PCR+ or PCR− (n= 67, n= 139). e shows the breadth score
for all antigens tested for C1q fixation, respectively, stratified by the level of protection in the follow up period, where ‘protected’ is malaria-episode free
during the follow up period (n= 116), ‘susceptible 1’ one malaria episode (n= 27) or ‘susceptible 2′ 2 or more malaria episodes (n= 54). P-values were
determined by Mann-Whitney test (C+D) or Kruskal–Wallis test (E). Error bars represent the interquartile range
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Mugil cohort. For the longitudinal study of PNG children, plasma samples were
obtained at enrolment from a prospective treatment-reinfection cohort of 206
children aged 5–14 years (median= 9.3) in Madang, PNG42. The prevalence of P.
falciparum and P. vivax, detected by PCR, at enrolment was 67.5% and 33.9%,
respectively. All children received 7 days of artesunate orally to clear any para-
sitaemia as described42. Artesunate was used because it has high efficacy and a
short half-life. Children were actively reviewed every 2 weeks for symptomatic
illness and parasitemia, and by passive case detection, over a period of 6 months. A
clinical episode of P. falciparum malaria was defined as fever and P. falciparum
parasitemia >5000 parasites/µl, and high-density parasitemia as >5000 parasites/µl.
Plasma samples used for this study were those taken at enrolment, prior to
treatment with antimalarials. Sera for positive controls were obtained from adults
within the Madang area. Sera for negative controls were obtained from anonymous
Australian blood donors who were malaria naive.
XMX samples. Serum samples were collected from a cross-sectional study in
Madang Province, Papua New Guinea (PNG) in 2007, and included 49 adults
(median age 28 years) and 69 children (median age 6 years)40. These samples were
included in the initial screening assays of complement fixation, and a selection of
samples were used to generate data presented in Fig. 2 (selection was random,
dependent on sufficient volume available).
VT samples. Serum samples are from a cross-sectional study and were collected
from pregnant women in the second trimester, non-pregnant women, and men in
Madang Province, PNG, in 2001 and 200253. Samples were also collected from men
accompanying children. These samples were included in the initial screening assays
of complement fixation.
Complement-fixation assays. 96-well plates (Maxisorp, Nunc) were coated with
purified merozoites at 5 × 106 merozoites per well or recombinant merozoite sur-
face antigens at 1–2 μg/ml24. Briefly, plates were blocked with 1% casein, then
incubated with serum samples (1/100–1/500) for 1 h, then washed with PBS-Tween
0.01%, followed by incubation for 30 min with purified C1q (10 μg/ml, Millipore)
or normal serum (NS), heat-inactivated serum (HIS) from malaria naive donors, or
C1q-depleted serum (Millipore) at 10% final concentration as a source of com-
plement. After washing plates, C1q fixation was detected by incubating with rabbit
anti-C1q antibodies (in-house) and then with anti-rabbit-IgG-HRP (Millipore),
incubated for 1 h each. ABTS (Life Technologies) was added, incubated for 30 mins
and absorbance quantified using a plate reader. All steps were conducted at room
temperature (~21 °C). For studies of membrane attack complex (MAC) formation,
normal serum was used as a complement source, and (rabbit-) anti-C5b/C9
antibodies (Millipore), and anti-rabbit-IgG-HRP (Millipore) were used for detec-
tion. IgG subclass ELISAs were done as previously described29,46,54 using mouse
anti-human IgG subclass monoclonal antibodies (Thermo Fischer Scientific) and
anti-mouse-IgG HRP (Millipore) detection antibodies. (Detailed protocols are
available from the authors on request).
Recombinant merozoite antigens. Proteins used in these assays were expressed
recombinantly as 6-His-fusion proteins or GST-fusion proteins in E. coli, or in a
wheat germ cell-free expression system as described previously55,56. Proteins
MSP1-42, EBA175RII, EBA140RII and MSP4 were kindly provided by Carole
Long, Annie Mo (NIH), David Narum (NIH), and Ross Coppel (Monash Uni-
versity), respectively. All proteins were assessed by SDS-PAGE to confirm identity
and integrity, and most proteins have been validated in studies of IgG reactivity, as
described39. Reactivity of human serum against 6-His- and GST-purification tags
has previously been found to be minimal and not to impact on overall
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Potential protective efficacy (median and range)
Single antigens (n = 20)
All combinations of 6 antigens (n = 38760)
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Fig. 6 Potential Protective Efficacy (PPE) of combinations of antibody responses that fix complement. Hazard Ratios for clinical malaria episodes obtained
by Cox Regression analyses were converted into Potential Protective Efficacy values (PPE= (1-aHR)*100). a The frequency (y-axes) of protective
responses (graph 1) or combination of responses (graphs 2–6), are shown. The different levels of PPE are indicated on the x-axes. b shows the PPE 95%
confidence interval (95% CI) of the best combination in each combination class. cMedian PPE and range of the top 100 combinations of each combination
class
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antigens; the FC27 allele of MSP2 was also used. Many antigens have minor
polymorphisms that do not appear to have a major impact on antibody recogni-
tion, including MSP1-19, MSP4, MSP5, PfRH5, PfRH2, EBA140, EBA175, GAMA,
PfRipr, Pf113 and RALP1. MSP2 exists as two allelic forms, and it has been
previously shown that the 3D7 allele is the most prevalent in our study popula-
tion29. We previously found that antibodies to different alleles of AMA1 are highly
correlated in this population (r= 092, p < 0.001)29. A high prevalence of antibodies
to antigens among infected children suggests that the 3D7 alleles used are repre-
sentative of infections in the population39.
Antibody-complement invasion inhibition assays. Invasion inhibition assays
were performed with normal serum, as described previously24. Merozoites were
purified from D10-PfPHG isolate58 (which includes a GFP label for detection by
flow cytometry), as previously described59. D10-PfGFP parasites were also used in
previously published C1q fixation ELISA assays24. For complement-dependent
invasion inhibition assays purified merozoite were incubated with 0.5% haemato-
crit RBC, 50% normal serum (from a malaria naive donor), and with 1:10 dilution
of heat-inactivated sera from patient sample in duplicate as described previously24.
Invasion was allowed to proceed for 30 min, cultures were then washed with cul-
ture medium to remove active complement, and subsequently incubated as for
standard culture for 40 h. Cultures were stained with Ethidium Bromide in PBS
and then analyzed via flow cytometry. Detailed methods can be found in Methods
in Malaria Research, 201360.
Growth inhibition assays. GIAs were performed over two cycles of replication
using validated methods58,61. Briefly, synchronized trophozoite stage parasites
(D10-PfGFP58) were diluted to a final hematocrit of 1% in normal erythrocytes in
culture media with a starting parasitemia of 0.1–0.3%. Parasites (25 µl) were ali-
quoted in 96-well U-bottom plates and sera (2.5 µl) were added at a dilution of 1/
10. 5 µl of culture media was added to each well after 48 h. After 96 h, parasites
were washed and stained with Ethidium Bromide in PBS and analysed by flow
cytometry. All samples were tested in duplicate and expressed as an average of
duplicates unless otherwise stated60.
Surface plasmon resonance. Surface Plasmon Resonance (SPR) assays were
performed to evaluate affinity (measured as kd) as previously described62. Briefly,
N-terminal coupling kits (Biacore) were used to bind proteins to a chip. Remaining
sites were blocked by injection of 1M ethanolamine (pH 8.5). Binding assays were
performed at a flow rate of 30 µl/min at 25 °C using degassed HBS-EP running
buffer. Serum samples were flowed over the bound proteins in two different
dilutions, and associations were monitored for 3 min followed by a 10 min
dissociation period. Responses were monitored as a function of time and kinetic
parameters (ka and kd) were evaluated using the BIAevaluation 4.1 software.
Data analysis. Differences in complement-fixation on merozoites and specific
antigens, and differences in complement fixation between groups were assessed by
chi-square tests (for categorical variables) or Wilcoxon rank-sum tests (for con-
tinuous variables). Correlations between variables (continuous data) were assessed
using Spearman’s Rho. In graphs, fitted lines were generated using non-linear
regression with dotted lines representing 95% confidence intervals.
Linear regression was performed in order to determine the association between
total IgG and avidity with C1q fixation. A linear spline was applied to allow for the
piecewise linear model after heteroskedasticity was detected by Breusch-Pagan/
Cook-Weissberg test. A knot was determined after visual inspection of the data.
The association between antibody variables and time to first episode of clinical
malaria (fever and >5000 parasites/ml) or high-density parasitemia (>5000
parasites/ml) was assessed using a Cox proportional hazards model; treatment
given at enrolment to clear parasitemia facilitated a time-to-even analysis. Potential
Protective Efficacy (PPE) was calculated as (1-Hazard Ratio)*100. Age and location
of residence were included in Cox regression a priori as they have previously been
identified as potential confounders from a range of variables in this cohort42. For
assessment of associations between C1q fixation and protection, subjects were
stratified into tertiles according to low (including those classified as ‘negative’),
medium, or high fixation of C1q, as determined by optical-density values for each
sample. Antibody breadth scores were calculated by assigning a score of 1, 2 and 3,
to low, medium and high C1q-fixing antibodies, respectively, and adding up each
individual’s scores for each antibody response to calculate the breadth score.
We investigated the protective associations for all possible combinations of
antigen-specific complement-fixing antibodies for up to 6 antigens in a
combination (from a total of n= 20 different antigen-specific antibody responses,
n= 190, 1140, 4845, 15504 and 38760 combinations, for combinations of 2, 3, 4, 5
and 6 antigens, respectively). The antibody combinations with the largest PPE were
identified using Cox proportional hazards model comparing high versus low
responders with first malaria episode as the outcome.
All analysis was performed with Stata/SE v13.0 Prism v7.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data analysed in the preparation of this manuscript may be available from the corre-
sponding author upon reasonable request and pending agreement from ethics com-
mittees (for clinical data). A reporting summary for this article is available as a
Supplementary Information file, and the data used to generate all figures are provided as
a Source Data File.
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